Interaction of prion protein with acetylcholinesterase: potential pathobiological implications in prion diseases

dc.contributor.authorTorrent, Joan
dc.contributor.authorVílchez Acosta, Alba del Valle
dc.contributor.authorMuñoz-Torrero López-Ibarra, Diego
dc.contributor.authorTrovaslet, M.
dc.contributor.authorNachon, Florian
dc.contributor.authorChatonnet, A.
dc.contributor.authorGrznarova, K.
dc.contributor.authorAcquatella-Tran Van Ba, I.
dc.contributor.authorGoffic, R. Le
dc.contributor.authorHerzog, Laetitia
dc.contributor.authorBéringue, V.
dc.contributor.authorRezaei, H.
dc.date.accessioned2015-09-02T11:42:27Z
dc.date.available2015-09-02T11:42:27Z
dc.date.issued2015-04-03
dc.date.updated2015-09-02T11:42:28Z
dc.description.abstractThe prion protein (PrP) binds to various molecular partners, but little is known about their potential impact on the pathogenesis of prion diseases. Here, we show that PrP can interact in vitro with acetylcholinesterase (AChE), a key protein of the cholinergic system in neural and non-neural tissues. This heterologous association induced aggregation of monomeric PrP and modified the structural properties of PrP amyloid fibrils. Following its recruitment into PrP fibrils, AChE loses its enzymatic activity and enhances PrP-mediated cytotoxicity. Using several truncated PrP variants and specific tight-binding AChE inhibitors (AChEis), we then demonstrate that the PrP-AChE interaction requires two mutually exclusive sub-sites in PrP N-terminal domain and an aromatic-rich region at the entrance of AChE active center gorge. We show that AChEis that target this site impair PrP-AChE complex formation and also limit the accumulation of pathological prion protein (PrPSc) in prion-infected cell cultures. Furthermore, reduction of AChE levels in prion-infected heterozygous AChE knock-out mice leads to slightly but significantly prolonged incubation time. Finally, we found that AChE levels were altered in prion-infected cells and tissues, suggesting that AChE might be directly associated with abnormal PrP. Our results indicate that AChE deserves consideration as a new actor in expanding pathologically relevant PrP morphotypes and as a therapeutic target.
dc.format.extent18 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec648300
dc.identifier.issn2051-5960
dc.identifier.pmid25853328
dc.identifier.urihttps://hdl.handle.net/2445/66823
dc.language.isoeng
dc.publisherBioMed Central
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1186/s40478-015-0188-0
dc.relation.ispartofActa Neuropathologica Communications, 2015, vol. 3, num. 18
dc.relation.urihttp://dx.doi.org/10.1186/s40478-015-0188-0
dc.rightscc-by (c) Torrent et al., 2015
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject.classificationAmiloïdosi
dc.subject.classificationMalalties neurodegeneratives
dc.subject.classificationProteïnes
dc.subject.otherAmyloidosis
dc.subject.otherNeurodegenerative Diseases
dc.subject.otherProteins
dc.titleInteraction of prion protein with acetylcholinesterase: potential pathobiological implications in prion diseases
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
648300.pdf
Mida:
2.39 MB
Format:
Adobe Portable Document Format